← All trials
NCT04534751
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2021
- Primary completion
- Dec 31, 2023
- Completion date
- Jan 30, 2024
- First posted
- Sep 1, 2020
- Last posted
- Oct 11, 2021
- Enrollment
- 350
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of TorontoLead sponsor
- Canadian Institutes of Health Research (CIHR)Collaborator
- OctapharmaCollaborator
- University of TorontoOverall official - principal investigator
- University of TorontoCollaborator
- Government of CanadaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.